LIDOMAX- lidomax gel
Oncora Pharma, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Lidomax™ (Lidocaine Hydrochloride) Topical Gel 2%

DESCRIPTION

Lidomax™ is a topical gel containing Lidocaine Hydrochloride 2%, a local anesthetic. It is intended for topical application to intact skin.

INDICATIONS AND USAGE

Lidomax™ is indicated for topical analgesia as directed by a healthcare provider.

WARNINGS

For external use only. Not for ophthalmic use. Avoid contact with eyes. Do not use if allergic to lidocaine or any components of the formulation. Keep out of reach of children.

DOSAGE AND ADMINISTRATION

Apply a thin layer to the affected area 3 to 4 times daily or as directed by a healthcare provider. For external use only.

HOW SUPPLIED

Lidomax™ (Lidocaine HCl 2%) is supplied as a clear topical gel in a 3 oz (85 g) tube.
NDC 85477-304-07

PRINCIPAL DISPLAY PANEL

Store at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F).
[See USP Controlled Room Temperature].
Keep container tightly closed.



pdp

LIDOMAX

lidomax gel

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:85477-304
Route of Administration	TOPICAL		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
LIDOCAINE (UNII: 98PI200987) (LIDOCAINE - UNII:98PI200987)	LIDOCAINE	20 mg in 1 g

Inactive Ingredients	
Ingredient Name	**Strength**
WATER (UNII: 059QF0KO0R)	
HYDROXYETHYLCELLULOSE (UNII: T4V6TWG28D)	

PHENOXYETHANOL (UNII: HIE492ZZ3T)	
ETHYLHEXYLGLYCERIN (UNII: 147D247K3P)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
LACTIC ACID (UNII: 33X04XA5AT)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:85477-304-07	85 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product	02/26/2026	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		02/26/2026	

Labeler - Oncora Pharma, LLC (119482542)

Revised: 2/2026 Oncora Pharma, LLC